AbbVie Inc. $ABBV is Hamlin Capital Management LLC's 7th Largest Position

Key Points

• Hamlin Capital Management reduced its AbbVie stake by 11.7% in the second quarter, selling 97,876 shares. Despite the reduction, AbbVie remains the firm’s seventh-largest position, representing 4.2% of its portfolio and valued at $185.9 million.
• AbbVie’s second-quarter performance exceeded expectations, with revenue rising 10.2% year over year to $16.99 billion and adjusted EPS reaching $3.65 versus the $3.61 consensus. The company guided for third-quarter EPS of $3.84–$3.88, supported by immunology and neuroscience growth.
• Analyst sentiment is broadly positive, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $272.76. However, AbbVie’s elevated valuation—roughly 69 times earnings—and a high dividend payout ratio remain notable risks.

Hamlin Capital Management LLC lessened its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 11.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 738,590 shares of the company's stock after selling 97,876 shares during the quarter. AbbVie comprises approximately 4.2% of Hamlin Capital Management LLC's portfolio, making the stock its 7th largest position. Hamlin Capital Management LLC's holdings in AbbVie were worth $185,859,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Willner & Heller LLC lifted its stake in shares of AbbVie by 0.7% in the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company's stock valued at $1,472,000 after purchasing an additional 43 shares during the last quarter. Bank of Jackson Hole Trust lifted its position in AbbVie by 0.6% in the fourth quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company's stock valued at $1,648,000 after buying an additional 44 shares during the last quarter. Eclectic Associates Inc. ADV boosted its stake in AbbVie by 0.8% during the fourth quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company's stock worth $1,337,000 after buying an additional 45 shares during the period. Imprint Wealth LLC increased its position in shares of AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company's stock valued at $29,000 after acquiring an additional 45 shares during the last quarter. Finally, Dogwood Wealth Management LLC increased its position in shares of AbbVie by 10.8% during the fourth quarter. Dogwood Wealth Management LLC now owns 473 shares of the company's stock valued at $108,000 after acquiring an additional 46 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie priced approximately $9.9 billion of senior notes to help fund an acquisition. While the financing increases interest obligations, it provides capital to pursue a transaction intended to strengthen the company’s growth profile. AbbVie prices $9.9B senior notes to fund acquisition
• Positive Sentiment: Analyst sentiment remains favorable. Erste Group upgraded AbbVie from “hold” to “buy,” while Cantor Fitzgerald raised its price target to $285, implying additional upside from recent trading levels. Cantor Fitzgerald boosts AbbVie price target
• Positive Sentiment: Second-quarter results exceeded expectations: revenue increased 10.2% year over year to $16.99 billion, and adjusted EPS of $3.65 surpassed the $3.61 consensus estimate. Growth in immunology and neuroscience helped offset concerns about the post-Humira transition, while third-quarter EPS guidance of $3.84–$3.88 indicates continued earnings momentum. AbbVie Q2 results and outlook
• Positive Sentiment: The FDA accepted Allergan Aesthetics’ supplemental application for BOTOX Cosmetic in masseter muscle prominence, expanding a major product into a potential new aesthetic indication. Approval could broaden BOTOX’s revenue opportunity, although the application still requires regulatory review. FDA accepts BOTOX Cosmetic application
• Positive Sentiment: Canada’s drug agency recommended conditional reimbursement of UBRELVY for acute migraine treatment, potentially improving access and supporting international growth for the newer migraine medicine. UBRELVY reimbursement recommendation
• Neutral Sentiment: RemeGen forecast a significant profit turnaround, citing stronger drug sales and an AbbVie licensing deal. The development supports AbbVie’s partnered pipeline but is unlikely to materially affect near-term results. RemeGen licensing update
• Negative Sentiment: Valuation remains a risk. Commentary noted ABBV’s trailing P/E near 70 and a model estimating fair value roughly $50 below the current level, raising concerns that much of the positive outlook may already be reflected in the stock. AbbVie year-end price prediction

AbbVie Stock Up 0.9%

NYSE:ABBV opened at $245.98 on Thursday. The company has a fifty day simple moving average of $240.90 and a two-hundred day simple moving average of $224.61. The company has a market cap of $434.59 billion, a price-to-earnings ratio of 69.49, a price-to-earnings-growth ratio of 0.81 and a beta of 0.30. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analysts' expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the firm earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts expect that AbbVie Inc. will post 14.06 EPS for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. AbbVie's dividend payout ratio (DPR) is currently 195.48%.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on ABBV shares. Evercore set a $235.00 price objective on shares of AbbVie in a report on Friday, May 15th. Canaccord Genuity Group boosted their target price on AbbVie from $282.00 to $290.00 and gave the company a "buy" rating in a research report on Monday. Sanford C. Bernstein restated a "market perform" rating on shares of AbbVie in a research note on Tuesday, June 23rd. DZ Bank upgraded AbbVie from a "hold" rating to a "strong-buy" rating in a research report on Thursday, April 30th. Finally, Weiss Ratings raised AbbVie from a "hold (c)" rating to a "buy (b-)" rating in a research note on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $272.76.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source